Wird geladen...
B-cell–targeted therapies in relapsing forms of MS
In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical tria...
Gespeichert in:
| Veröffentlicht in: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Lippincott Williams & Wilkins
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5656409/ https://ncbi.nlm.nih.gov/pubmed/29082296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000405 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|